Levi Strauss, Constellation Brands and 3 Stocks to Watch Heading Into Wednesday

Caribou Biosciences said it is exploring strategic alternatives and will discontinue two cell therapy programs; its shares fell 35.1% to $0.74 after hours. Constellation Brands beat second-quarter earnings expectations, raised FY2027 GAAP earnings guidance and announced the acquisition of ready-to-drink brand SpikedAde, but shares dropped 4.5% to $110.50. Levi Strauss, Applied Digital and Richardson Electronics were due to report earnings after the close; their shares rose 0.3%, 0.5% and 1.5%, respectively, in after-hours trading.

Analysis

This is primarily an event-risk calendar, not a broad sector signal. The clearest change in equity value is at Caribou: discontinuing both cell-therapy programs shifts the story from clinical execution to residual cash, liabilities, and sale value. The after-hours decline may still underprice the risk that strategic alternatives produce little value after wind-down costs; conversely, a credible buyer or asset deal could create a sharp squeeze. Verify cash runway, obligations, and process updates before treating the gap as a durable valuation floor.

For Applied Digital, the earnings sensitivity is less about the reported loss alone than whether contracted capacity is converting into revenue on schedule and how much incremental capital and power infrastructure are required. Strong demand without funded delivery can be equity-dilutive; utilization or deployment slippage would challenge the growth narrative. Constellation’s positive guidance paired with a selloff suggests investors may be discounting the quality or durability of the outlook, or the strategic fit of the RTD acquisition, rather than rewarding the headline beat. One session is not confirmation: watch subsequent guidance commentary and category-level demand indicators.

Levi’s and Richardson Electronics are binary earnings events with insufficient evidence here for directional conviction. For Levi’s, the useful read-through is inventory and channel mix, not EPS versus estimate in isolation. No portfolio-wide conclusion follows from this roundup.

Key Decisions for Investors

• CRBU: Avoid buying the post-gap decline until cash, wind-down obligations, and strategic-process details are verified. Reassess on a disclosed transaction or runway update; a credible asset sale could invalidate a downside thesis, while a short without borrow/liquidity checks risks a violent squeeze.
• APLD: Treat the print as a catalyst, not a pre-earnings directional trade. Monitor deployment timing, contracted capacity converting to revenue, capital spending, and financing terms; a material schedule slip or greater-than-expected funding need would falsify the growth case.
• STZ: Do not buy solely on the guidance raise. Watch whether the market stabilizes after management explains demand assumptions and the SpikedAde rationale; persistent weakness alongside lowered underlying category outlook would support staying cautious, while stable underlying guidance and clear acquisition economics would weaken that view.
• LEVI / RELL: No position from the supplied information. After results, prioritize Levi’s inventory, channel mix, and forward outlook; for Richardson Electronics, require evidence of durable revenue or margin improvement before extrapolating a small after-hours move.